Clinical trials: Immunosuppressive Treatment
Kidney Transplantation
Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation
The aim of the study is to evaluate the efficacy of new immunosuppressive protocol based on two applications of anti-CD52 MabCampath (Alemtuzumab) a single dose of anti-TNF-α Remicade (infliximab) monoclonal antibodies in the…
- Trial name
- NCT02711202
- Testing
- MabCampath,, Remicade, Sirolimus
- Volunteers
- 20 people
- Sponsor
- Institute for Clinical and Experimental Medicine
Heart Transplantation, Liver Transplantation
Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant
The purpose of this study was to offer patients who had participated in one of the phase II PK or phase III studies on FK506E (MR4) the possibility to continue FK506E (MR4) until commercial availability of the drug and to record…
- Conditions
- Heart Transplantation, Liver Transplantation, Kidney Transplantation
- Trial name
- NCT02118896
- Testing
- FK506E
- Where
- 105 sites in United States, Australia and 21 more
- Volunteers
- 850 people
- Sponsor
- Astellas Pharma Europe Ltd.
Rheumatologic Disorder, Inflammatory Bowel Diseases
Flu Vaccine Response in Patients on Biologic Therapies
This proposed study will assess the immunogenicity, safety, and clinical efficacy of an influenza vaccine booster dose strategy in patients with autoimmune diseases who are receiving immunosuppressive therapies.
- Conditions
- Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
- Trial name
- NCT03277703
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stony Brook University
Uveitis
First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial
The proposed study is a masked trial, with stratified block randomization by site, designed to determine which treatment, methotrexate or mycophenolate mofetil, is more effective as first-line steroid-sparing treatment for…
- Trial name
- FAST (NCT01232920)
- Testing
- Methotrexate, Mycophenolate mofetil
- Where
- 2 sites in India
- Volunteers
- 80 people
- Sponsor
- University of California, San Francisco
Medication Adherence, Liver Transplantation
A Study of mDOT for Immunosuppressant Adherence in Solid Organ Transplant Recipients
In solid organ transplant recipients, poor adherence to immunosuppressant medications carries the risk of graft rejection (needing a new transplant), post-transplant complications, and increased healthcare costs.
- Conditions
- Medication Adherence, Liver Transplantation, Kidney Transplantation
- Trial name
- NCT04587024
- Testing
- mHealth intervention, standard of care
- Where
- 2 sites in United States
- Volunteers
- 75 people
- Sponsor
- Johns Hopkins University
Severe Aplastic Anemia
Sirolimus (Rapamune ) for Relapse Prevention in People With Severe Aplastic Anemia Responsive to Immunosuppressive Therapy
Background: People with severe aplastic anemia (SAA) do not make enough red and white blood cells, and/or platelets. Their body's immune system stops the bone marrow from making these cells.
- Trial name
- NCT02979873
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Diabetes Mellitus, Type 1
New Onset of Type 1 Diabetes Mycophenolate Mofetil-Daclizumab Clinical Trial
The objective of this study is to identify immune intervention strategies that will preserve residual beta cell function at the onset of type 1 diabetes.
- Trial name
- TN02 (NCT00100178)
- Testing
- Mycophenolate mofeteil (MMF), Daclizumab (DZB)
- Where
- 11 sites in United States, Canada
- Volunteers
- 126 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Aplastic Anemia
Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin/Cyclosporine A in Naive Aplastic Anemia (AA) Subjects
This was an open label, non-randomized, phase II study of eltrombopag in combination with rabbit ATG/CsA in subjects with moderate or more severe AA who did not received prior ATG/ALG-based immunosuppressive therapy.
- Trial name
- NCT02404025
- Testing
- Eltrombopag, Rabbit ATG, CsA
- Where
- 11 sites in Japan
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplantation
REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy
The purpose of this study was, starting from the Italian clinical practice in liver transplantation, to optimize the immunosuppressive therapy, considering specific patient characteristics as alcoholic cirrhosis, hepatitis C…
- Trial name
- REFLECT (NCT02115113)
- Testing
- Everolimus, Tacrolimus
- Where
- 14 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Novartis Pharmaceuticals
Anemia, Aplastic, Anemia, Hypoplastic
A Pilot Study of the Thrombopoietin-Receptor Agonist Eltrombopag in Refractory Aplastic Anemia Patients
Severe aplastic anemia (SAA) is a life-threatening blood disease which can be effectively treated with immunosuppressive drug regimens or allogeneic stem cell transplantation.
- Conditions
- Anemia, Aplastic, Anemia, Hypoplastic, Thrombocytopenia
- Trial name
- NCT00922883
- Testing
- Eltrombopag
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Immunosuppresion, Thrombocytopenia
Three Immunosuppressive Treatment Regimens for Severe Aplastic Anemia
Severe aplastic anemia (SAA) is a life-threatening bone marrow failure disorder characterized by pancytopenia and a hypocellular bone marrow.
- Conditions
- Immunosuppresion, Thrombocytopenia, Pancytopenia, Neutropenia
- Trial name
- NCT00260689
- Testing
- Anti-thymocyte globulin (rabbit), Anti-thymocyte globulin (horse), Cyclosporine
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Transplantation
An Observational Study on Renal Function in Kidney Transplant Participants on Immunosuppressive Therapy Containing Mycophenolate Mofetil
This observational study will evaluate renal function in participants who underwent renal allograft transplantation and are started on combined immunosuppressive treatment containing mycophenolate mofetil (CellCept).
- Trial name
- ORANGE (NCT01672957)
- Testing
- Mycophenolate Mofetil, Immunosuppressive Therapy
- Where
- 2 sites in Hungary
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Adult Malignant Fibrous Histiocytoma of Bone, Desmoid Tumor, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00474994
- Testing
- sunitinib malate
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Rejection of Liver Transplant, Effects of Immunosuppressant Therapy
SRL (Sirolimus) Withdrawal
The significance of this clinical trial lies in its potential to increase the success of immunosuppression (IS) therapy withdrawal in liver transplant (LT) recipients, thus decreasing the negative impact of IS on their long-term…
- Trial name
- SRL (NCT02062944)
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwestern University
Myelodysplastic Syndrome (MDS) With Refractory Anemia (RA), Severe Aplastic Anemia (SAA)
Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelodysplastic Syndrome
This study will evaluate the safety and effectiveness of treating patients with severe aplastic anemia (SAA) or myelodysplastic syndrome (MDS) with both peripheral blood stem cells from a family member and umbilical cord blood…
- Trial name
- NCT00604201
- Testing
- Umbilical Cord Blood
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Renal Transplantation
Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
The purpose of this study is to assess whether a calcineurin inhibitor (CNI)-free regimen with enteric-coated mycophenolate sodium (EC-MPS) and everolimus is as safe and well-tolerated as the standard regimen containing…
- Trial name
- NCT00154310
- Testing
- Everolimus, Cyclosporine, Enteric-coated mycophenolate sodium
- Where
- 3 sites in Germany, Switzerland
- Volunteers
- 300 people
- Sponsor
- Novartis
Aplastic Anemia, Neutropenia
A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia
Background: Severe aplastic anemia (SAA) can lead to problems with bone marrow health and result in low blood cell counts, which require frequent transfusions.
- Conditions
- Aplastic Anemia, Neutropenia, Pancytopenia, Severe Aplastic Anemia
- Trial name
- NCT01187017
- Testing
- Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Relapsing-Remitting Multiple Sclerosis
High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study
The purpose of this study is to determine the effectiveness of a new treatment for multiple sclerosis (MS), a serious disease in which the immune system attacks the brain and spinal cord.
- Trial name
- NCT00288626
- Testing
- Granulocyte-colony stimulating factor (G-CSF) and prednisone, Carmustine, etoposide, cytarabine, and melphalan (BEAM), Autologous hematopoietic stem cell transplant
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Transplantation
Behavioral Contract Adherence Intervention
There is a critical gap in the knowledge on how to implement effective interventions for renal transplant recipients (RTRs) to improve immunosuppressant therapy (IST) adherence and clinical outcomes.
- Trial name
- NCT01739803
- Testing
- Behavioral Contract
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Tennessee
Devic's Disease
Hematopoietic Stem Cell Transplant in Devic's Disease
This study is designed to examine whether treating Devic's disease patients with high dose cyclophosphamide together with rabbit antithymocyte globulin (rATG)/rituximab (drugs which reduce the function of the immune system)…
- Trial name
- NCT00787722
- Testing
- Hematopoietic Stem Cell Transplantation, Cyclophosphamide, G-CSF
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Northwestern University